Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective study of nearly 375,000 type 2 diabetes patients evaluating the incidence of events related to cardiovascular disease (CVD) and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. These findings were presented at the American Heart Association Scientific Sessions in Chicago...
More...
More...